 BNT162B2, a MINA vaccine developed by Novax, has been shown to be effective at inducing protective immunity in mice that lack B cells. This immunity was found to be dependent on the production of interferon gamma, IFN, suggesting that cellular immunity plays a key role in the protection against emerging SARS-CoV-2 variants such as amicron and its sub-lineages. This article was authored by Xiaolai Wang, Terence Tsetai-Yuan, Ying Do, and others.